Universal Technical Institute
UTI
$22.92
-5.68%
Universal Technical Institute, Inc. (UTI) is a leading provider of postsecondary education and training programs for technicians in the automotive, diesel, collision repair, motorcycle, and marine industries, operating through its UTI and Concorde Career Colleges segments. The company distinguishes itself as a specialized workforce development platform, addressing the skilled trades gap with a network of campuses and employer partnerships. Currently, the stock is under intense scrutiny following a dramatic price drop on August 6, 2026, which has raised questions about the sustainability of its recent growth momentum and the impact of regulatory or operational challenges on its enrollment and profitability outlook.…
UTI
Universal Technical Institute
$22.92
Investment Opinion: Should I buy UTI Today?
Rating: Hold. The consensus Strong Buy and average target of $42.17 suggest upside, but the recent crash and margin collapse warrant caution. The thesis is that UTI's long-term demand for skilled trades is intact, but near-term profitability is uncertain, making a wait-and-see approach prudent.
Sign up to view all
UTI 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The stable revenue growth and strong analyst sentiment are offset by the dramatic margin collapse and single-day crash. The key uncertainty is whether the Q2 profit decline is temporary or structural. If margins recover in the next two quarters, the stock is likely undervalued, but if they continue to deteriorate, the downside to $21 is real. I would upgrade to bullish if gross margin returns above 50% and net income exceeds $10M per quarter, and downgrade to bearish if revenue growth falls below 5% or the company announces a liquidity issue.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Universal Technical Institute's 12-month outlook, with a consensus price target around $41.83 and implied upside of +82.5% versus the current price.
Average Target
$41.83
0 analysts
Implied Upside
+82.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$37 - $48
Analyst target range
The wide spread between the low and high targets (38 to 49) reflects high uncertainty about the company's near-term recovery. The low target of $38.00 implies a 36% upside, which may already account for continued margin pressure and slower growth. The high target of $49.00 assumes a full recovery to previous highs, driven by successful execution of growth initiatives and improved operational efficiency. The consensus 'Strong Buy' rating, despite the recent crash, suggests that analysts believe the sell-off is overdone and that the company's long-term fundamentals remain intact. However, the lack of recent downgrades or negative commentary in the provided data may indicate that the market is still digesting the news, and future revisions could be more cautious.
Bulls vs Bears: UTI Investment Factors
UTI presents a classic value trap scenario: strong long-term demand and analyst optimism clash with deteriorating near-term profitability. The bull case rests on a 51% upside to analyst targets and a low PEG, but the bear case is anchored by a 34% single-day crash, collapsing margins, and a premium valuation. Currently, bearish evidence is stronger because the earnings miss and margin erosion are concrete, while analyst targets may not yet reflect the full impact of the August 6 event. The pivotal tension is whether the Q2 profit collapse is a one-time blip or the start of a sustained downturn—if margins recover, the stock is deeply undervalued; if not, further downside to the 52-week low is likely.
Bullish
- Strong Buy consensus with 51% upside: Analysts rate UTI a Strong Buy (mean 1.17) with an average target of $42.17, implying 51% upside from the current $27.87. The low target of $38 still offers 36% upside, suggesting the market overreacted to the recent drop.
- Revenue growth steady at 6.7% YoY: Q2 FY2026 revenue reached $221.4M, up 6.7% year-over-year, maintaining a stable trajectory around $220M for three consecutive quarters. This consistency indicates resilient demand for technical education despite macro headwinds.
- PEG ratio of 0.55 signals undervaluation: With a trailing PE of 28.1x and expected EPS growth of ~1.95 (forward EPS), the PEG of 0.55 suggests the stock is cheap relative to its growth prospects. This is a key metric for value-oriented investors.
- Strong ROE of 19.2%: UTI's return on equity stands at 19.2%, well above the industry average, reflecting efficient use of shareholder capital. This is supported by a 49.7% gross margin, indicating pricing power in its niche.
Bearish
- Profit collapse in Q2 FY2026: Net income plunged to $0.4M from $11.4M a year ago, with net margin falling to 0.2% from 5.5%. Operating income dropped to just $0.3M, indicating severe cost pressures or one-time charges that could persist.
- Gross margin deterioration of 390 bps: Gross margin fell to 46.7% from 50.6% YoY, the lowest in recent quarters. This suggests rising instructor costs, campus expansion expenses, or pricing pressure, which could erode profitability further.
- Stock crashed 34% in one day: On August 6, 2026, UTI fell from $42.37 to $27.87, a -34.2% single-day drop, erasing months of gains. This signals a major negative event (likely regulatory or operational) that the market is still pricing in.
- High valuation premium to industry: UTI trades at 28.1x trailing PE vs. the industry average of 22x, a 28% premium. With earnings declining, this premium is unjustified unless growth accelerates, making the stock vulnerable to multiple compression.
UTI Technical Analysis
UTI's price trend over the past year has been characterized by a strong uptrend followed by a sharp reversal. The stock is currently trading at $27.87, which is 54.3% of its 52-week range (low $21.29, high $51.34), indicating a significant pullback from its highs. The 1-year price change is -16.6%, while the 6-month change is +9.2%, suggesting that the longer-term trend has been positive but has recently deteriorated. The stock's position near the lower end of its range suggests that it may be approaching oversold territory, but the sharp decline also signals potential further downside risk.
Beta
1.24
1.24x market volatility
Max Drawdown
-55.2%
Largest decline past year
52-Week Range
$21-$51
Price range past year
Annual Return
-12.1%
Cumulative gain past year
| Period | UTI Return | S&P 500 |
|---|---|---|
| 1m | -38.6% | +1.9% |
| 3m | -42.8% | +2.3% |
| 6m | -25.0% | +10.6% |
| 1y | -12.1% | +19.5% |
| ytd | -7.7% | +11.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UTI Fundamental Analysis
Revenue growth has been steady, with the most recent quarter (Q2 FY2026, ending March 31, 2026) showing revenue of $221.4 million, up 6.7% year-over-year. This follows a pattern of sequential growth, with Q1 FY2026 revenue at $220.8 million and Q4 FY2025 at $222.4 million, indicating a stable but not accelerating trajectory. The company's gross margin in the latest quarter was 46.7%, down from 50.6% in the year-ago quarter, reflecting cost pressures. Net income in Q2 FY2026 was a mere $0.4 million, a sharp decline from $11.4 million in Q2 FY2025, and the net margin fell to 0.2% from 5.5%, highlighting significant profitability erosion.
Quarterly Revenue
$221402000.0B
2026-03
Revenue YoY Growth
+6.7%
YoY Comparison
Gross Margin
46.7%
Latest Quarter
Free Cash Flow
$1441000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UTI Overvalued?
Given that UTI is profitable on a trailing basis (net income positive), the PE ratio is the primary valuation metric. The trailing PE is 28.1x, while the forward PE is 30.0x, indicating that the market expects earnings to remain relatively flat or slightly decline. The PEG ratio of 0.55 suggests that the stock is undervalued relative to its expected earnings growth, but this is based on analyst estimates that may be overly optimistic given the recent earnings miss. Compared to the industry average PE of 22x (from valuation data), UTI trades at a 28% premium, which may be justified by its strong market position and growth prospects, but the premium is narrowing as earnings disappoint.
PE
28.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~70x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are acute: net income fell 96% YoY to $0.4M, and operating margin compressed to 0.15% from 8.1% a year ago, indicating severe cost overruns or revenue shortfalls. The company's debt-to-equity of 0.85 and current ratio of 1.07 suggest limited liquidity buffer, while TTM free cash flow of just $1.4M leaves little room for error. If the margin pressure persists, UTI could face covenant breaches or need to raise capital, diluting shareholders.